淋巴结阴性乳腺癌辅助疗法适应证的分析  

Analysis of indications for adjuvant treatment in node-negative breast cancer

作　　者：李刚 鲍丽萍 姜海 潘伟 王海明 赵永华 张广智 

机构地区：[1]本溪钢铁公司总医院肿瘤外科,辽宁本溪117000

出　　处：《中国癌症杂志》2001年第4期313-315,共3页China Oncology

摘　　要：目的 :探讨淋巴结阴性 (N0 )乳腺癌辅助疗法的适应证。方法 :以 2 33例乳腺癌根治术切取 2 0个以上淋巴结转移阴性的乳腺癌的患者为对象 ,对N0 乳腺癌的复发因素和术后辅助疗法的适应证进行分析。结果 :N0 乳腺癌的术后复发率为 17/2 33(7.3% ) ;年龄、月经史、部位、肿瘤直径及病理学因素与预后相关。在有意义的病理学预后因素中将浸润性小叶癌、组织学恶性度Ⅲ级 (高度恶性 )及淋巴细胞浸润阴性癌 3项进行组合分析 ,其复发率具有 3项者为 2 8% ,2项者为 16 % ,1项者为 7%。结论 :对具有高危复发因素的N0 乳腺癌需要进行辅助疗法。Purpose:In order to determine the indications for adjuvant treatment in node-negative breast cancer.Methods:We analyzed 233 cases of node-negative breast cancer. Results:The recurrence ratio of node-negative breast cancer was 7.3 percent. The prognosis was connected with age,menstrual history , position, diameter of tumor and pathology. Among invasive lobule cancer, GradeⅢ and lymphocyte-negative cancer, the recurrence ratio was 28 percent in patients with three factors, 16 percent in patient with two factors, 7 percent in patients with one factor.Conclusions:Node-negative breast cancer cases with high recurrence factors need adjuvant treatment.

关 键 词：乳腺癌 辅助治疗 淋巴结阴性 适应证 

分 类 号：R737.9[医药卫生—肿瘤]